WASHINGTON, Sept. 24, 2003 (PRIMEZONE) -- Growth Report, an independent investment newsletter service for individual investors that has delivered returns of 68.2% since the beginning of 2003, reported that iMergent (OTCBB:IMGG), a recent addition to the stock portfolio, achieved record revenues for the fourth quarter and fiscal year ending June 30th 2003.
Growth Report added iMergent to the model portfolio on August 5th at $5.45, and the stock is currently up 18%. The initial report, along with this financial analysis report, is available on the Growth Report web site free of charge to trial subscribers at http://www.growthreport.com
This report on iMergent discusses:
-- The company's ability to meet our revenue and earnings
expectations for the quarter and year
-- A tax loss carry forward that will allow the company to avoid
paying federal income taxes for several years
-- Management's ability to decrease selling, general, and
administrative costs by $1 million during the 4th quarter while
maintaining sales of $15 million
-- Company spending during the 4th quarter that is translating into
strong growth in the first quarter of the year
-- Expansion strategies that include overseas product launches as
well as servicing of the company's own customer accounts
In the September 17th issue of Growth Report, Editor Ian Wyatt wrote: "If the company is able to continue growing at two-thirds its current top line growth rate, that would translate into roughly 28%. Due to the efficiencies the company gains as it expands upon its customer base, and the potential for handling the financing activities and collections for its customers in the future, we believe iMergent is in a formidable position to grow its bottom line more quickly than the top line ... From a valuation standpoint, shares of iMergent currently trade at 15-times trailing earnings per share and 1.4-times trailing sales."
Growth Report's stock portfolio returned 40% in 2002, and is up another 68.2% thus far in 2003 by taking long-term positions in fundamentally strong growth stocks. This investment approach has yielded consistently strong returns for subscribers of the newsletter service.
Individual investors who are interested in signing up for a 30-day free trial to Growth Report will receive this report on iMergent, plus a free Special Report titled "Not So Generic Returns -- Investing in Generic and Specialty Pharmaceuticals." Free trial subscribers also receive two issues per week by e-mail, one issue per month in print, access to over one year of archived articles, and past and future Special Reports. To start a free 30-day trial subscription, click here: https://www.bizfn.com/index.cfm?Page=pubs&pubs=2&r=pr9
About Growth Report
Growth Report is a leading investment newsletter published by Business Financial Publishing, LLC. Growth Report is entirely independent, and dedicated to uncovering stocks that will deliver the greatest return to subscribers. Two weekly issues delivered by e-mail and on the web provide subscribers with regular updates on the latest news and changes to the portfolio, while a monthly print edition provides in depth articles in an easy to read format.
Disclaimer
Growth Report is neither a registered investment advisor nor a broker / dealer. Readers are advised that the publication is issued solely for information purposes and should not to be construed as an offer to sell or the solicitation of an offer to buy any security. No information provided herein or elsewhere from Growth Report constitutes a recommendation by Growth Report to buy, sell or hold any security. We encourage you to consult with independent financial advisors with respect to any investment in the securities mentioned herein.